Fig. 6.

The blocking antibody B6B4 rescues mice with HCN of DEFA1/DEFA3 from sepsis. (A and B) Mice were subjected to CLP, and B6B4 (300 μg per mouse), mouse IgG (300 μg per mouse), or normal saline (NS; equal volume) were intravenously administered at 0, 24, and 48 h after CLP (A). Survival over time of mice with HCN of DEFA1/DEFA3 was assessed (B). *P = 0.011 between NS-treated group and B6B4-treated group, *P = 0.016 between IgG-treated group and B6B4-treated group, log-rank test. (C and D) Mice were subjected to CLP, and B6B4 (300 μg per mouse), mouse IgG (300 μg per mouse), or normal saline (NS; equal volume) were intravenously administered at 12, 36, and 60 h after CLP (C). Survival over time of mice with HCN of DEFA1/DEFA3 was assessed (D). *P = 0.031, ***P < 0.001, log-rank test. (E–H) Representative images and comparisons of CD31⁺ endothelial cells in the lung (E and F) and renal glomeruli (G and H) from mice with HCN of DEFA1/DEFA3 that were subjected to CLP and treated with mouse IgG (n = 3) or B6B4 (n = 3) as shown in C, and the mice were killed at 72 h after CLP. Red indicates CD31⁺ staining; blue indicates DAPI staining. (Scale bars, 50 μm.) In B, n = 17 for mice with NS treatment, n = 17 for mice with IgG treatment, and n = 20 for mice with B6B4 treatment. In D, n = 6 for mice with NS treatment, n = 6 for mice with IgG treatment, and n = 8 for mice with B6B4 treatment. In F and H, data are presented as dot plots with horizontal bars representing means ± SEM. In F, *P = 0.011, two-tailed unpaired t test. In H, *P = 0.032, two-tailed unpaired t test.